Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2412MR)

This product GTTS-WQ2412MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2412MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9332MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ2488MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 212
GTTS-WQ14087MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-421
GTTS-WQ14481MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RO-7105705
GTTS-WQ9489MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IPH-5401
GTTS-WQ569MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 62-71-3
GTTS-WQ14522MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SA-237
GTTS-WQ13924MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN2477
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW